MCID: LNG035
MIFTS: 52

Lung Large Cell Carcinoma

Categories: Cancer diseases, Rare diseases, Respiratory diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Lung Large Cell Carcinoma

MalaCards integrated aliases for Lung Large Cell Carcinoma:

Name: Lung Large Cell Carcinoma 11 14
Large Cell Carcinoma of Lung 11 71
Large Cell Lung Carcinoma 11 16
Large Cell Lung Cancer 53

Classifications:



External Ids:

Disease Ontology 11 DOID:4556
NCIt 49 C4450
SNOMED-CT 68 254629004
UMLS 71 C0345958

Summaries for Lung Large Cell Carcinoma

MalaCards based summary: Lung Large Cell Carcinoma, also known as large cell carcinoma of lung, is related to rhabdoid cancer and carcinoid tumors, intestinal. An important gene associated with Lung Large Cell Carcinoma is NME1 (NME/NM23 Nucleoside Diphosphate Kinase 1), and among its related pathways/superpathways are Signaling by Receptor Tyrosine Kinases and Endometrial cancer. The drugs Carboplatin and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include lung, endothelial and lymph node, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Lung Large Cell Carcinoma

Diseases in the Lung Large Cell Carcinoma family:

Small Cell Cancer of the Lung Lung Clear Cell Carcinoma

Diseases related to Lung Large Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 646)
# Related Disease Score Top Affiliating Genes
1 rhabdoid cancer 30.5 TP53 SYP H2AC18
2 carcinoid tumors, intestinal 30.4 SYP NKX2-1 ENO2 CHGA
3 benign mesothelioma 30.4 NKX2-1 KRT7 KRT5
4 bronchus cancer 30.3 KRT7 ENO2 EGFR ALK
5 large cell carcinoma with rhabdoid phenotype 30.3 TP53 KRAS HRAS ENO2
6 vulva cancer 30.2 TP53 KRT7 HRAS EGFR
7 mesothelioma, malignant 30.2 NKX2-1 KRT7 KRT5 H2AC18
8 cholangitis, primary sclerosing 30.2 TP53 KRT7 KRAS HRAS
9 large cell neuroendocrine carcinoma 30.1 TP53 SYP NKX2-1 NCAM1 NAPSA MIR409
10 rectal benign neoplasm 30.1 TP53 KRT7 KRAS HRAS EGFR
11 skin benign neoplasm 30.1 TP53 KRT7 KRT5 HRAS ENO2
12 rectum adenocarcinoma 30.1 TP53 KRT7 KRAS HRAS EGFR
13 neuroendocrine carcinoma 30.1 SYP NKX2-1 NCAM1 KRT7 ENO2 CHGA
14 rectum cancer 30.1 TP53 KRAS HRAS H2AC18 EGFR
15 lymphoepithelioma-like carcinoma 29.9 TP53 SYP NCAM1 KRT7 KRT5 ENO2
16 lung giant cell carcinoma 29.9 NKX2-1 NAPSA KRT7 KRT5 KRAS EGFR
17 squamous cell carcinoma 29.9 TP53 NME1 NKX2-1 KRT7 KRAS HRAS
18 large cell carcinoma 29.9 TP53 SYP NKX2-1 NAPSA MIR200B KRT7
19 lung squamous cell carcinoma 29.8 TP53 MIR200B KRAS HRAS H2AC18 EGFR
20 keratinizing squamous cell carcinoma 29.7 TP53 SYP NKX2-1 NAPSA KRT7 KRT5
21 adenosquamous carcinoma 29.6 NME1 NKX2-1 KRT7 KRT5 KRAS INSM1
22 adenocarcinoma 29.6 TP53 NKX2-1 NAPSA KRT7 KRAS HRAS
23 lung cancer susceptibility 3 29.6 TP53 NKX2-1 NAPSA MIR200B KRT7 KRAS
24 basaloid squamous cell carcinoma 29.6 TP53 SYP NKX2-1 NCAM1 NAPSA KRT7
25 lung benign neoplasm 29.5 TP53 SYP NKX2-1 NCAM1 KRT7 KRAS
26 small cell cancer of the lung 29.5 TP53 SYP NKX2-1 NCAM1 KRT7 INSM1
27 small cell carcinoma 29.5 TP53 SYP NKX2-1 NCAM1 NAPSA KRT7
28 lung cancer 29.0 TP53 SYP NME1 NKX2-1 NCAM1 NAPSA
29 lung mixed small cell and squamous cell carcinoma 11.3
30 mucinous cystadenofibroma 10.5 SYP KRT7
31 malignant melanocytic neoplasm of the peripheral nerve sheath 10.5 SYP ENO2
32 pancreas lymphoma 10.5 SYP CHGA
33 vaginal glandular tumor 10.4 ENO2 CHGA
34 neuronal intestinal dysplasia, type b 10.4 SYP ENO2
35 mixed ductal-endocrine carcinoma 10.4 SYP CHGA
36 lung meningioma 10.4 SYP NKX2-1
37 vulvar eccrine porocarcinoma 10.4 SYP CHGA
38 cervical large cell neuroendocrine carcinoma 10.4 SYP CHGA
39 ovary neuroendocrine neoplasm 10.4 SYP KRT7
40 optic nerve astrocytoma 10.4 SYP ENO2
41 sternum lymphoma 10.4 NKX2-1 NCAM1
42 sternum cancer 10.4 NKX2-1 NCAM1
43 acinar cell cystadenocarcinoma 10.4 SYP CHGA
44 pineal region teratoma 10.4 SYP ENO2
45 endometrial transitional cell carcinoma 10.4 SYP KRT7
46 signet ring lung adenocarcinoma 10.4 EGFR ALK
47 extraosseous ewings sarcoma-primitive neuroepithelial tumor 10.4 SYP ENO2
48 partial cryptophthalmia 10.4 SYP ENO2
49 rectum lymphoma 10.4 NCAM1 ALK
50 goblet cell carcinoid 10.4 ENO2 CHGA

Graphical network of the top 20 diseases related to Lung Large Cell Carcinoma:



Diseases related to Lung Large Cell Carcinoma

Symptoms & Phenotypes for Lung Large Cell Carcinoma

GenomeRNAi Phenotypes related to Lung Large Cell Carcinoma according to GeneCards Suite gene sharing:

25 (show all 13)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.28 EGFR HRAS KRAS NCAM1
2 Decreased viability GR00055-A-2 10.28 EGFR HRAS KRAS
3 Decreased viability GR00055-A-3 10.28 KRAS
4 Decreased viability GR00106-A-0 10.28 KRAS
5 Decreased viability GR00221-A-1 10.28 ALK EGFR HRAS KRAS NME1
6 Decreased viability GR00221-A-2 10.28 HRAS KRAS NME1
7 Decreased viability GR00221-A-3 10.28 HRAS
8 Decreased viability GR00221-A-4 10.28 ALK EGFR
9 Decreased viability GR00249-S 10.28 ALK NME1
10 Decreased viability GR00301-A 10.28 KRAS
11 Decreased viability GR00381-A-1 10.28 KRAS
12 Decreased viability GR00402-S-2 10.28 NME1
13 Reduced mammosphere formation GR00396-S 9.17 CHGA EGFR HRAS KRAS KRT7 NCAM1

MGI Mouse Phenotypes related to Lung Large Cell Carcinoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 10.1 ALK ASCL1 CHGA DLL3 EGFR ENO2
2 no phenotypic analysis MP:0003012 9.92 ASCL1 CHGA EGFR HRAS INSM1 KRAS
3 neoplasm MP:0002006 9.91 ALK EGFR HRAS KRAS NKX2-1 NME1
4 endocrine/exocrine gland MP:0005379 9.9 ALK ASCL1 CHGA EGFR HRAS INSM1
5 craniofacial MP:0005382 9.61 ASCL1 DLL3 EGFR ENO2 HRAS INSM1
6 respiratory system MP:0005388 9.28 ALK ASCL1 EGFR ENO2 HRAS INSM1

Drugs & Therapeutics for Lung Large Cell Carcinoma

Drugs for Lung Large Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 70)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 4 41575-94-4 10339178 38904
2
Paclitaxel Approved, Vet_approved Phase 4 33069-62-4 36314
3
Everolimus Approved Phase 4 159351-69-6 70789204 6442177
4 Tubulin Modulators Phase 4
5 Antimitotic Agents Phase 4
6 Albumin-Bound Paclitaxel Phase 4
7 Immunologic Factors Phase 4
8 Immunosuppressive Agents Phase 4
9
Cisplatin Approved Phase 3 15663-27-1 2767 5702198 441203
10
Etoposide Approved Phase 3 33419-42-0 36462
11
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
12
Vinorelbine Approved, Investigational Phase 3 71486-22-1 44424639 60780
13
Gefitinib Approved, Investigational Phase 3 184475-35-2 123631
14
Cetuximab Approved Phase 3 205923-56-4
15 Mitogens Phase 3
16
Etoposide phosphate Phase 3 16760419
17 Protein Kinase Inhibitors Phase 3
18 Shark Cartilage Phase 3
19 Endothelial Growth Factors Phase 3
20 Immunoglobulin G Phase 3
21
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
22
Lenograstim Approved, Investigational Phase 2 135968-09-1
23
Picropodophyllin Approved, Investigational Phase 2 518-28-5, 477-47-4 10607 72435
24
Nivolumab Approved Phase 2 946414-94-4
25
Gemcitabine Approved Phase 2 95058-81-4, 122111-03-9 60750
26
Durvalumab Approved, Investigational Phase 2 1428935-60-7
27
Rucaparib Approved, Investigational Phase 2 283173-50-2 9931954
28
Metformin Approved Phase 2 1115-70-4, 657-24-9 4091
29
Pembrolizumab Approved Phase 1, Phase 2 1374853-91-4 254741536
30
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
31
Fludarabine Approved Phase 1, Phase 2 75607-67-9, 21679-14-1 30751 657237
32
Coenzyme M Approved, Investigational Phase 1, Phase 2 3375-50-6 598 23662354
33
Aldesleukin Approved Phase 1, Phase 2 110942-02-4
34
Levoleucovorin Approved, Experimental, Investigational Phase 2 68538-85-2, 58-05-9, 73951-54-9 149436 6006
35
Pemetrexed Approved, Investigational Phase 2 150399-23-8, 137281-23-3 60843 446556 135565230
36
Crizotinib Approved, Investigational Phase 2 877399-52-5 11626560
37
Glutamic acid Approved, Nutraceutical Phase 2 56-86-0 33032
38
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
39
D-Tyrosine Approved, Experimental, Investigational, Nutraceutical Phase 2 133585-56-5, 556-02-5, 60-18-4 1153 6057
40
Veliparib Investigational Phase 1, Phase 2 912444-00-9 11960529
41 Poly(ADP-ribose) Polymerase Inhibitors Phase 1, Phase 2
42 Dermatologic Agents Phase 2
43 Adjuvants, Immunologic Phase 2
44 Keratolytic Agents Phase 2
45 Antimetabolites Phase 2
46 Immune Checkpoint Inhibitors Phase 2
47 Hypoglycemic Agents Phase 2
48 Antineoplastic Agents, Immunological Phase 1, Phase 2
49 Antiviral Agents Phase 1, Phase 2
50 Anti-Infective Agents Phase 1, Phase 2

Interventional clinical trials:

(show all 37)
# Name Status NCT ID Phase Drugs
1 A Multi-centric, Open-label, Phase II Study Investigating the Combination of Afinitor With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced (Stage IV) Large Cell Lung Cancer With Neuroendocrine Differentiation (LC-NEC) Completed NCT01317615 Phase 4 RAD001;Paclitaxel;Carboplatin
2 Randomized Phase II/III Trial of Paclitaxel Plus Carboplatin With or Without Bevacizumab (NSC #704865) in Patients With Advanced Nonsquamous NSCLC Completed NCT00021060 Phase 2, Phase 3 paclitaxel;carboplatin
3 Multicenter, Open-Ended, Double-Blind, Placebo-Controlled, Phase III Study of AE-941 in Addition to Combined Modality Treatment (Chemotherapy/Radiotherapy) for Locally Advanced Unresectable Non-Small Cell Lung Cancer Completed NCT00005838 Phase 3 shark cartilage extract AE-941;cisplatin;vinorelbine tartrate;carboplatin;paclitaxel
4 A PHASE III STUDY OF ADJUVANT CHEMOTHERAPY AFTER RESECTION FOR PATIENTS WITH T2N0 STAGE I NON-SMALL CELL CARCINOMA OF THE LUNG Completed NCT00002852 Phase 3 paclitaxel;carboplatin
5 A Phase III Prospective Randomized, Double-Blind, Placebo-Controlled Trial of the Epidermal Growth Factor Receptor Antagonist, ZD1839 (IRESSA) in Completely Resected Primary Stage IB, II and IIIA Non-Small Cell Lung Cancer Completed NCT00049543 Phase 3 gefitinib
6 A Phase III Trial of Cisplatin/Etoposide/Radiotherapy With Consolidation Docetaxel Followed by Maintenance Therapy With ZD1839 (NSC-715055) or Placebo in Patients With Inoperable Locally Advanced Stage III Non-Small Cell Lung Cancer Completed NCT00020709 Phase 3 cisplatin;docetaxel;etoposide;gefitinib
7 A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab With or Without Concurrent Cetuximab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Active, not recruiting NCT00946712 Phase 3 Carboplatin;Paclitaxel
8 Fostering Efficacy of Anti - PD-1 - Treatment: Nivolumab Plus Radiotherapy in Advanced NSCLC Completed NCT03044626 Phase 2 Radiotherapy;Nivolumab
9 A Randomized Phase II Study of Schedule-Modulated Concomitant Pemetrexed (Alimta) and Erlotinib (Tarceva) vs Single Agent Pemetrexed (Alimta®) in Patients With Progressive or Recurrent Non-small Cell Lung Cancer (NSCLC) Completed NCT00950365 Phase 2 Erlotinib Hydrochloride;Pemetrexed Disodium
10 Phase II Trial of the Akt Inhibitor MK-2206 Plus Erlotinib (OSI-774) in Patients With Advanced Non-small Cell Lung Cancer Who Have Progressed After Previous Response (Including Stable Disease) With Erlotinib Therapy Completed NCT01294306 Phase 2 Akt Inhibitor MK2206;Erlotinib Hydrochloride
11 Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer Completed NCT01642251 Phase 1, Phase 2 Cisplatin;Etoposide;Veliparib;Placebo
12 Phase II Study of Sequential Dose-Dense Chemotherapy and Dose-Intense Erlotinib for the Initial Treatment of Advanced Non-Small Cell Lung Cancer Completed NCT01557959 Phase 2 cisplatin;erlotinib hydrochloride;docetaxel
13 A Phase II Trial of Docetaxel Plus Cetuximab and Docetaxel Plus Bortezomib (NSC #681239, IND #58443) in Advanced Non-Small Cell Lung Cancer Patients With Performance Status (PS) 2 Completed NCT00118183 Phase 2 docetaxel;bortezomib
14 Phase II Trial of OSI-774 (NSC-718781) in Patients With Advanced Non-Small Cell Lung Cancer and a Performance Status of 2 Completed NCT00087412 Phase 2 erlotinib hydrochloride
15 A Phase II Trial of Combination Carboplatin, Paclitaxel, Cetuximab and Bevacizumab (NSC-704865) Followed By Cetuximab and Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer Completed NCT00368992 Phase 2 paclitaxel
16 ZD1839 (NSC #715055, IND #61187) With Induction Paclitaxel And Carboplatin Followed By Either Radiation Or Concomitant Radiation With Weekly Paclitaxel And Carboplatin In Stage III Non-Small Cell Lung Cancer, A Phase II Study Completed NCT00040794 Phase 2 paclitaxel;carboplatin;gefitinib
17 A Phase 2 Randomized Study of the BER Inhibitor TRC102 in Combination With Standard Pemetrexed-Platinum-Radiation in Stage III Non-Squamous Non-Small Cell Lung Cancer Recruiting NCT05198830 Phase 2 Cisplatin;Methoxyamine;Pemetrexed
18 A Randomized, Phase II Trial of Icotinib Versus Observation as Adjuvant Treatment in Stage IB Non-Small Cell Lung Cancer Harboring Activating Epidermal Growth Factor Receptor Mutation Recruiting NCT02264210 Phase 2 Icotinib
19 A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811) Active, not recruiting NCT01386385 Phase 1, Phase 2 Carboplatin;Paclitaxel;Veliparib
20 A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Addition of Bevacizumab (NSC-704865) in Three Cohorts of Patients With Inoperable Locally Advanced Stage III Non-small Cell Lung Cancer Active, not recruiting NCT00334815 Phase 2 Cisplatin;Docetaxel;Etoposide
21 Phase II Randomized Clinical Trials Comparing Immunotherapy Plus Stereotactic Ablative Radiotherapy (I-SABR) Versus SABR Alone for Stage I, Selected Stage IIa, or Isolated Lung Parenchymal Recurrent Non-Small Cell Lung Cancer: I-SABR Active, not recruiting NCT03110978 Phase 2
22 A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study) Active, not recruiting NCT03845296 Phase 2 Rucaparib
23 Randomized Phase II Trial of Concurrent Chemoradiotherapy +/- Metformin HCL in Locally Advanced NSCLC Active, not recruiting NCT02186847 Phase 2 Carboplatin;Metformin;Paclitaxel
24 Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION) Active, not recruiting NCT03345810 Phase 2 Durvalumab;Vinorelbine;Gemcitabine;nab-Paclitaxel;Carboplatin
25 A Phase 1/2 Trial (CheckCell-2) in Patients With Metastatic Non-small Cell Lung Cancer (NSCLC) Administering Tumor-Infiltrating Lymphocytes (TILs) in Which the Gene Encoding CISH Was Inactivated Using the CRISPR/Cas9 System Not yet recruiting NCT05566223 Phase 1, Phase 2 Fludarabine;Cyclophosphamide;Aldesleukin;Pembrolizumab
26 A Phase II Randomized Trial of Paclitaxel, Carboplatin, Bevacizumab With or Without IMC-A12 in Patients With Advanced Non-squamous, Non-small Cell Lung Cancer Terminated NCT00955305 Phase 2 Carboplatin;Paclitaxel
27 S1300: A Randomized, Phase II Trial of Crizotinib Plus Pemetrexed Versus Pemetrexed Monotherapy in ALK-Positive Non-squamous NSCLC Patients Who Have Progressed Systemically After Previous Clinical Benefit From Crizotinib Monotherapy Terminated NCT02134912 Phase 2 crizotinib;pemetrexed disodium
28 A Phase I Study of Methoxyamine Combined With Chemo-Radiation for Locally Advanced Non-Squamous Non-Small Cell Lung Cancer Completed NCT02535325 Phase 1 Cisplatin;Methoxyamine;Methoxyamine Hydrochloride;Pemetrexed;Pemetrexed Disodium
29 Phase I Study of Thoracic Radiotherapy and Concurrent Chemotherapy With Soy Isoflavones in Stage III NSCLC (Non-Small Cell Lung Cancer) Patients Completed NCT01958372 Phase 1 cisplatin;etoposide;pemetrexed disodium
30 A Phase I Study of Light Dose for Photodynamic Therapy(PDT) Using 2-[ 1-hexyloxyethel]-2-devinyl Pyropheophorbide-a (HPPH) for Treatment of Non-small Cell Carcinoma in Situ or Non-small Cell Microinvasive Carcinoma. A Dose Ranging Study Completed NCT01668823 Phase 1 HPPH;photodynamic therapy
31 A Phase I Study Of OSI-774 (NSC #718781)-Based Multimodality Therapy For Inoperable Stage III Non Small Cell Lung Cancer Terminated NCT00042835 Phase 1 cisplatin;etoposide;erlotinib hydrochloride;docetaxel;paclitaxel;carboplatin
32 A Safety and Feasibility Study of Bevacizumab With Paclitaxel, Carboplatin and Chest Radiotherapy in Patients With Locally Advanced Non-Small Lung Cancer Terminated NCT00369551 Phase 1 paclitaxel;carboplatin
33 A Phase I Image-Guided Adaptive Radiotherapy Study Using Active Breathing Control (ABC) and Simultaneous Integrated Boost for Patients With Inoperable Non-Small Cell Lung Cancer Withdrawn NCT02059967 Phase 1 Paclitaxel;carboplatin
34 Evaluation of PD-L1 Tumor Expression in Patients With Large-cell Neuroendocrine Carcinoma (NEC) (EPNEC-GFPC 03-2017) Completed NCT03305133
35 Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) Recruiting NCT02194738 Carboplatin;Cisplatin;Crizotinib;Erlotinib;Gemcitabine Hydrochloride;Paclitaxel;Pemetrexed;Pemetrexed Disodium
36 Integrative Analysis of Large-cell Lung Carcinoma Recruiting NCT02917369
37 Image-Guided Hypofractionated Radiotherapy With Stereotactic Boost and Chemotherapy for Inoperable Stage II-III Non-Small Cell Lung Cancer Active, not recruiting NCT01345851 carboplatin;paclitaxel

Search NIH Clinical Center for Lung Large Cell Carcinoma

Genetic Tests for Lung Large Cell Carcinoma

Anatomical Context for Lung Large Cell Carcinoma

Organs/tissues related to Lung Large Cell Carcinoma:

MalaCards : Lung, Endothelial, Lymph Node, Spinal Cord, Bone Marrow, Thyroid, Breast

Publications for Lung Large Cell Carcinoma

Articles related to Lung Large Cell Carcinoma:

(show top 50) (show all 457)
# Title Authors PMID Year
1
Alteration in gene expression profile and biological behavior in human lung cancer cell line NL9980 by nm23-H1 gene silencing. 53 62
18440302 2008
2
Transfection of nm23-H1 increased expression of beta-Catenin, E-Cadherin and TIMP-1 and decreased the expression of MMP-2, CD44v6 and VEGF and inhibited the metastatic potential of human non-small cell lung cancer cell line L9981. 53 62
17167724 2006
3
[Molecular mechanism of reversing metastatic phenotype in human high-metastatic large cell lung cancer cell line L9981 by nm23-H1]. 53 62
15757527 2005
4
Dabrafenib plus trametinib treatment for a patient with BRAF V600E-mutated large-cell lung carcinoma and a poor performance status. 62
36186221 2022
5
CircRNA circ-PDCD11 is highly expressed in lung large-cell carcinoma and predicts poor survival. 62
36017647 2022
6
Diagnostic pitfall in a large cell lung cancer with testicular metastasis synchronous malignant pleural mesothelioma patient: A case report. 62
35707844 2022
7
The anticancer effects of cyanidin 3-O-glucoside combined with 5-fluorouracil on lung large-cell carcinoma in nude mice. 62
35609368 2022
8
Cytotoxicity and anti-inflammatory activities of Gallesia integrifolia (Phytolaccaceae) fruit essential oil. 62
34000931 2022
9
Identification of condition-specific regulatory mechanisms in normal and cancerous human lung tissue. 62
35524179 2022
10
Structure-based discovery of a specific SHP2 inhibitor with enhanced blood-brain barrier penetration from PubChem database. 62
35180489 2022
11
Essential Oils and Extracts of Juniperus macrocarpa Sm. and Juniperus oxycedrus L.: Comparative Phytochemical Composition and Anti-Proliferative and Antioxidant Activities. 62
35448753 2022
12
Comprehensive Characterization of Human Lung Large Cell Carcinoma Identifies Transcriptomic Signatures with Potential Implications in Response to Immunotherapy. 62
35329826 2022
13
Spirostane saponins with a rearranged A/B ring system isolated from the rhizomes of Ophiopogon japonicus. 62
34649046 2022
14
IFNγ-IL-17-IL-22+CD4+ subset and IL-22-producing cells in tumor draining lymph nodes of patients with breast cancer. 62
36189579 2022
15
Tumor Suppressor 4.1N/EPB41L1 is Epigenetic Silenced by Promoter Methylation and MiR-454-3p in NSCLC. 62
35795202 2022
16
Epigenetic Alterations and Inflammation as Emerging Use for the Advancement of Treatment in Non-Small Cell Lung Cancer. 62
35514980 2022
17
Salvage surgery following immuno-chemo-radiotherapy for advanced non-small cell lung cancer. 62
35061129 2022
18
Circulating Tumor Cell Detection in Lung Cancer Animal Model. 62
34667135 2021
19
Pembrolizumab-induced autoimmune side effects of colon and pancreas in a patient with lung cancer. 62
34415552 2021
20
Histone Modification in NSCLC: Molecular Mechanisms and Therapeutic Targets. 62
34769131 2021
21
Steroidal saponins with cytotoxic effects from the rhizomes of Asparagus cochinchinensis. 62
34388486 2021
22
Neuroendocrine Carcinomas of the Digestive Tract: What Is New? 62
34359666 2021
23
Ethiopian Medicinal Plants Traditionally Used for the Treatment of Cancer; Part 3: Selective Cytotoxic Activity of 22 Plants against Human Cancer Cell Lines. 62
34203971 2021
24
Schisandrin B inhibits epithelial‑mesenchymal transition and stemness of large‑cell lung cancer cells and tumorigenesis in xenografts via inhibiting the NF‑κB and p38 MAPK signaling pathways. 62
33907830 2021
25
A nomogram prognostic model for large cell lung cancer: analysis from the Surveillance, Epidemiology and End Results Database. 62
33718009 2021
26
Cashew apple (Anacardium occidentale L.) extract from a by-product of juice processing: assessment of its toxicity, antiproliferative and antimicrobial activities. 62
33568870 2021
27
Rare gastrointestinal metastases from primary lung cancer. Two case reports of patients managed with emergency surgery. 62
34031285 2021
28
Durable Response to Immunotherapy With Antiangiogenic Drug in Large-Cell Lung Carcinoma With Multiple Fulminant Postoperative Metastases: A Case Report. 62
34094914 2021
29
Case Report: Long-Term Survival With Anlotinib in a Patient With Advanced Undifferentiated Large-Cell Lung Cancer and Rare Tonsillar Metastasis. 62
34249723 2021
30
Analysis of Molecular Mechanism of YiqiChutan Formula Regulating DLL4-Notch Signaling to Inhibit Angiogenesis in Lung Cancer. 62
33628824 2021
31
Identification and Integrate Analysis of Key Biomarkers for Diagnosis and Prognosis of Non-Small Cell Lung Cancer Based on Bioinformatics Analysis. 62
34825846 2021
32
Hsa-miR-4271 downregulates the expression of constitutive androstane receptor and enhances in vivo the sensitivity of non-small cell lung cancer to gefitinib. 62
32755614 2020
33
PLGA Nanofiber/PDMS Microporous Composite Membrane-Sandwiched Microchip for Drug Testing. 62
33260653 2020
34
Synchronous duodenum and descending colon metastasis from primary lung neuroendocrine small-cell carcinoma: A case report and review of the literature. 62
32063106 2020
35
Anticancer Activity of Novel Plant Extracts and Compounds from Adenosma bracteosum (Bonati) in Human Lung and Liver Cancer Cells. 62
32599892 2020
36
Clinicopathological characteristics and prediction of cancer-specific survival in large cell lung cancer: a population-based study. 62
32642131 2020
37
Secretagogin, a marker for neuroendocrine cells, is more sensitive and specific in large cell neuroendocrine carcinoma compared with the markers CD56, CgA, Syn and Napsin A. 62
32194720 2020
38
Clinical characteristics and treatments of large cell lung carcinoma: a retrospective study using SEER data. 62
35117493 2020
39
Case Report: Therapeutic Response to Chemo-Immunotherapy in an Advanced Large Cell Lung Carcinoma Patient With Low Values of Multiple Predictive Biomarkers. 62
33584678 2020
40
[Immediate results of surgical treatment of advanced age patients with non-small cell lung cancer]. 62
33047582 2020
41
Effective Treatment of NSCLC with Surgery After Nivolumab Combined with Chemotherapy: A Case Report and Brief Review of the Literature. 62
33408481 2020
42
A case of large-cell lung carcinoma successfully treated with pembrolizumab but complicated with cholangitis. 62
32944497 2020
43
Cancer-associated Retinopathy with Neuroendocrine Combined Large-cell Lung Carcinoma and Adenocarcinoma. 62
31327819 2019
44
Inhibition of bone morphogenetic protein signaling reduces viability, growth and migratory potential of non-small cell lung carcinoma cells. 62
31531741 2019
45
Unraveling the large cell lung carcinoma-specific miRNA profile and the downstream regulation network. 62
31555828 2019
46
Five genes may predict metastasis in non-small cell lung cancer using bioinformatics analysis. 62
31423239 2019
47
Klotho expression and nodal involvement as predictive factors for large cell lung carcinoma. 62
31360195 2019
48
Doxycycline inhibits electric field-induced migration of non-small cell lung cancer (NSCLC) cells. 62
31147570 2019
49
Comparison of PANAMutyper and PNAClamp for Detecting KRAS Mutations from Patients With Malignant Pleural Effusion. 62
31028221 2019
50
Comparative mitochondrial proteomic analysis of human large cell lung cancer cell lines with different metastasis potential. 62
30950202 2019

Variations for Lung Large Cell Carcinoma

Cosmic variations for Lung Large Cell Carcinoma:

8 (show top 50) (show all 2927)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM98261314 WNK3 lung,NS,carcinoma,large cell carcinoma c.4458G>T p.L1486F 23:54236967-54236967 9
2 COSM144807452 WNK3 lung,NS,carcinoma,large cell carcinoma c.4599G>T p.L1533F 23:54236967-54236967 9
3 COSM98245214 WNK3 lung,NS,carcinoma,large cell carcinoma c.4599G>T p.L1533F 23:54236967-54236967 9
4 COSM89575026 WNK3 lung,NS,carcinoma,large cell carcinoma c.4599G>T p.L1533F 23:54236967-54236967 9
5 COSM89696421 TTN lung,NS,carcinoma,large cell carcinoma c.74816C>A p.T24939N 2:178535180-178535180 9
6 COSM139391502 TTN lung,NS,carcinoma,large cell carcinoma c.68214C>G p.L22738= 2:178572995-178572995 9
7 COSM91857770 TTN lung,NS,carcinoma,large cell carcinoma c.54398T>A p.L18133Q 2:178589623-178589623 9
8 COSM89696432 TTN lung,NS,carcinoma,large cell carcinoma c.46518C>G p.L15506= 2:178572995-178572995 9
9 COSM91600209 TTN lung,NS,carcinoma,large cell carcinoma c.65346T>C p.D21782= 2:178573082-178573082 9
10 COSM140806401 TTN lung,NS,carcinoma,large cell carcinoma c.62102T>A p.L20701Q 2:178589623-178589623 9
11 COSM113843333 TTN lung,NS,carcinoma,large cell carcinoma c.45942C>G p.L15314= 2:178572995-178572995 9
12 COSM143323462 TTN lung,NS,carcinoma,large cell carcinoma c.68127T>C p.D22709= 2:178573082-178573082 9
13 COSM143538666 TTN lung,NS,carcinoma,large cell carcinoma c.57179T>A p.L19060Q 2:178589623-178589623 9
14 COSM89958622 TTN lung,NS,carcinoma,large cell carcinoma c.35483T>A p.L11828Q 2:178589623-178589623 9
15 COSM113843323 TTN lung,NS,carcinoma,large cell carcinoma c.74240C>A p.T24747N 2:178535180-178535180 9
16 COSM96689092 TTN lung,NS,carcinoma,large cell carcinoma c.46317C>G p.L15439= 2:178572995-178572995 9
17 COSM143323444 TTN lung,NS,carcinoma,large cell carcinoma c.96512C>A p.T32171N 2:178535180-178535180 9
18 COSM139391513 TTN lung,NS,carcinoma,large cell carcinoma c.68127T>C p.D22709= 2:178573082-178573082 9
19 COSM114063677 TTN lung,NS,carcinoma,large cell carcinoma c.34907T>A p.L11636Q 2:178589623-178589623 9
20 COSM140594116 TTN lung,NS,carcinoma,large cell carcinoma c.73050T>C p.D24350= 2:178573082-178573082 9
21 COSM96950315 TTN lung,NS,carcinoma,large cell carcinoma c.35282T>A p.L11761Q 2:178589623-178589623 9
22 COSM139601272 TTN lung,NS,carcinoma,large cell carcinoma c.57179T>A p.L19060Q 2:178589623-178589623 9
23 COSM91600192 TTN lung,NS,carcinoma,large cell carcinoma c.65433C>G p.L21811= 2:178572995-178572995 9
24 COSM96689108 TTN lung,NS,carcinoma,large cell carcinoma c.46230T>C p.D15410= 2:178573082-178573082 9
25 COSM113843339 TTN lung,NS,carcinoma,large cell carcinoma c.45855T>C p.D15285= 2:178573082-178573082 9
26 COSM89696443 TTN lung,NS,carcinoma,large cell carcinoma c.46431T>C p.D15477= 2:178573082-178573082 9
27 COSM143323454 TTN lung,NS,carcinoma,large cell carcinoma c.68214C>G p.L22738= 2:178572995-178572995 9
28 COSM140594104 TTN lung,NS,carcinoma,large cell carcinoma c.101435C>A p.T33812N 2:178535180-178535180 9
29 COSM91600174 TTN lung,NS,carcinoma,large cell carcinoma c.93731C>A p.T31244N 2:178535180-178535180 9
30 COSM140594111 TTN lung,NS,carcinoma,large cell carcinoma c.73137C>G p.L24379= 2:178572995-178572995 9
31 COSM139391487 TTN lung,NS,carcinoma,large cell carcinoma c.96512C>A p.T32171N 2:178535180-178535180 9
32 COSM96689073 TTN lung,NS,carcinoma,large cell carcinoma c.74615C>A p.T24872N 2:178535180-178535180 9
33 COSM85297370 TTBK1 lung,NS,carcinoma,large cell carcinoma c.2417C>T p.S806F 6:43283157-43283157 9
34 COSM94305492 TRRAP lung,NS,carcinoma,large cell carcinoma c.8069C>T p.P2690L 7:98976613-98976613 9
35 COSM113088121 TRRAP lung,NS,carcinoma,large cell carcinoma c.8015C>T p.P2672L 7:98976613-98976613 9
36 COSM91892841 TRRAP lung,NS,carcinoma,large cell carcinoma c.8015C>T p.P2672L 7:98976613-98976613 9
37 COSM146270672 TRRAP lung,NS,carcinoma,large cell carcinoma c.8015C>T p.P2672L 7:98976613-98976613 9
38 COSM113297535 TRPM6 lung,NS,carcinoma,large cell carcinoma c.3006G>C p.W1002C 9:74782752-74782752 9
39 COSM97140529 TRPM6 lung,NS,carcinoma,large cell carcinoma c.3021G>C p.W1007C 9:74782752-74782752 9
40 COSM93841629 TRPM6 lung,NS,carcinoma,large cell carcinoma c.3006G>C p.W1002C 9:74782752-74782752 9
41 COSM126644406 TRIB1 lung,NS,carcinoma,large cell carcinoma c.420C>G p.F140L 8:125436465-125436465 9
42 COSM128244784 TRIB1 lung,NS,carcinoma,large cell carcinoma c.615C>G p.F205L 8:125436465-125436465 9
43 COSM91855448 TRIB1 lung,NS,carcinoma,large cell carcinoma c.1113C>G p.F371L 8:125436465-125436465 9
44 COSM145017865 TP53 lung,NS,carcinoma,large cell carcinoma c.616G>A p.G206S 17:7674230-7674230 9
45 COSM122272158 TP53 lung,NS,carcinoma,large cell carcinoma c.92A>G p.Y31C 17:7675124-7675124 9
46 COSM122271574 TP53 lung,NS,carcinoma,large cell carcinoma c.16G>C p.A6P 17:7675200-7675200 9
47 COSM144311386 TP53 lung,NS,carcinoma,large cell carcinoma c.739G>A p.E247K 17:7673764-7673764 9
48 COSM142842304 TP53 lung,NS,carcinoma,large cell carcinoma c.487T>A p.Y163N 17:7675125-7675125 9
49 COSM106052835 TP53 lung,NS,carcinoma,large cell carcinoma c.574C>T p.Q192* 17:7674957-7674957 9
50 COSM142562914 TP53 lung,NS,carcinoma,large cell carcinoma c.617G>A p.G206D 17:7674229-7674229 9

Expression for Lung Large Cell Carcinoma

Search GEO for disease gene expression data for Lung Large Cell Carcinoma.

Pathways for Lung Large Cell Carcinoma

Pathways related to Lung Large Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 21)
# Super pathways Score Top Affiliating Genes
1 12.7 KRAS HRAS EGFR ASCL1 ALK
2
Show member pathways
12.54 TP53 KRAS HRAS EGFR ALK
3
Show member pathways
12.33 TP53 KRAS HRAS EGFR
4
Show member pathways
12.31 TP53 KRAS HRAS EGFR
5 12.25 TP53 KRAS HRAS EGFR
6
Show member pathways
12.15 TP53 KRAS HRAS EGFR DLL3
7 12 DLL3 HRAS KRAS TP53
8 11.75 KRAS HRAS EGFR CHGA
9 11.65 SYP NCAM1 ASCL1
10
Show member pathways
11.64 TP53 KRAS HRAS
11 11.47 KRAS HRAS EGFR
12 11.37 NME1 HRAS EGFR
13 11.29 KRAS HRAS EGFR
14 11.21 KRAS HRAS ALK
15 11.12 TP53 KRAS HRAS EGFR
16 11.09 KRAS HRAS EGFR
17 10.99 KRAS HRAS EGFR
18 10.87 TP53 KRAS HRAS EGFR
19
Show member pathways
10.86 KRAS HRAS EGFR
20
Show member pathways
10.68 KRAS HRAS
21 10.53 TP53 KRAS HRAS EGFR

GO Terms for Lung Large Cell Carcinoma

Biological processes related to Lung Large Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 noradrenergic neuron development GO:0003358 9.62 INSM1 ASCL1
2 cerebral cortex GABAergic interneuron differentiation GO:0021892 9.56 NKX2-1 ASCL1
3 regulation of cell population proliferation GO:0042127 9.5 TP53 HRAS EGFR ASCL1 ALK
4 adrenal chromaffin cell differentiation GO:0061104 9.46 INSM1 ASCL1
5 regulation of long-term neuronal synaptic plasticity GO:0048169 9.1 SYP KRAS HRAS

Sources for Lung Large Cell Carcinoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 24-Oct-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....